Get the Stockscreener App
2.06
0.00%
0.00
After Hours:
2.06
Mural Oncology Plc stock is traded at $2.06, with a volume of 112.91K.
It is up +0.00% in the last 24 hours and down -14.98% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.06
Open:
$2.06
24h Volume:
112.91K
Relative Volume:
0.46
Market Cap:
$35.69M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.44%
1M Performance:
-14.98%
6M Performance:
-43.72%
1Y Performance:
-37.39%
1-Day Range:
$2.06
$2.07
1-Week Range:
$2.05
$2.09
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.06 | 35.69M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
How to forecast Mural Oncology plc trends using time seriesJuly 2025 Big Picture & Technical Pattern Recognition Alerts - Newser
Volume spikes in Mural Oncology plc stock – what they meanEarnings Miss & Verified Trade Idea Suggestions - Newser
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mural Oncology plc (NASDAQ: MURA) - PR Newswire
Published on: 2025-08-27 15:58:19 - Newser
Using AI based signals to follow Mural Oncology plcWeekly Stock Summary & Proven Capital Preservation Methods - Newser
Published on: 2025-08-27 14:46:00 - Newser
Is Mural Oncology plc meeting your algorithmic filter criteriaTrade Performance Summary & Precise Buy Zone Tips - Newser
Published on: 2025-08-27 13:10:25 - Newser
Mural Oncology plc stock trendline breakdown2025 Trading Volume Trends & Safe Entry Trade Reports - Newser
Form 8.3Mural Oncology plc - Business Wire
Citadel Group discloses 1.53% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.53% stake in Mural Oncology By Investing.com - Investing.com UK
Visual analytics tools that track Mural Oncology plc performanceTrade Analysis Report & Fast Gain Stock Trading Tips - Newser
Can momentum traders help lift Mural Oncology plcMarket Risk Analysis & Consistent Return Strategy Ideas - Newser
Mural Oncology plc stock momentum explainedJuly 2025 Outlook & Low Risk High Win Rate Picks - Newser
Tick level data insight on Mural Oncology plc volatilityPortfolio Update Report & Long-Term Safe Investment Plans - Newser
Is Mural Oncology plc stock poised for growthWeekly Gains Report & Safe Capital Growth Trade Ideas - Newser
Using flow based indicators on Mural Oncology plc2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Published on: 2025-08-26 10:48:02 - Newser
Citadel Group discloses 1.61% stake in Mural Oncology - Investing.com
Citadel Group discloses 2.1% stake in Mural Oncology - Investing.com
Key metrics from Mural Oncology plc’s quarterly dataWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Aug Wrap: Is Mural Oncology plc showing insider buyingJuly 2025 Drop Watch & Daily Stock Momentum Reports - sundaytimes.kr
Technical Models Detect Momentum Build in Mural Oncology plc - 더경남뉴스
Backtesting results for Mural Oncology plc trading strategiesJuly 2025 Sentiment & Expert Curated Trade Ideas - Newser
What technical models suggest about Mural Oncology plc’s comebackTrade Analysis Summary & Scalable Portfolio Growth Ideas - Newser
Will Mural Oncology plc be affected by tariffsWeekly Investment Report & Stepwise Trade Signal Implementation - theviewers.co.kr
Candlestick signals on Mural Oncology plc stock todayJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Is Mural Oncology plc exposed to political riskMarket Movers & Low Risk Entry Point Tips - theviewers.co.kr
What moving averages say about Mural Oncology plcWeekly Trade Review & Weekly Top Gainers Trade List - Newser
Citadel Group discloses 2.33% stake in Mural Oncology By Investing.com - Investing.com Canada
Citadel Group discloses 2.33% stake in Mural Oncology - Investing.com
Mural Oncology plc Recovery Likely Here’s What Data ShowsJuly 2025 Drop Watch & Expert-Curated Trade Recommendations - 더경남뉴스
Mural Oncology To Be Acquired By XOMA Royalty - MSN
Xoma Acquires Mural Oncology in Latest Deal to Acquire 'Zombie' Biotech - AInvest
Mural Oncology plc Approaches Psychological Resistance LevelQuarterly Profit Summary & High Conviction Investment Ideas - 클래시안
Xoma Royalty Corporation shares fall 1.92% after-hours following Vanguard Group's disclosure of Mural Oncology plc position. - AInvest
Can Mural Oncology plc be the next market leaderJuly 2025 Action & Fast Gain Stock Tips - theviewers.co.kr
Citadel Group discloses 2.81% stake in Mural Oncology - Investing.com
Citadel Group discloses 1.44% stake in Mural Oncology By Investing.com - Investing.com Australia
Mural Oncology accepts XOMA takeover bid - The Pharma Letter
Will Mural Oncology plc Stock Benefit from AI and Green Energy TrendsGlobal Markets & Reliable Intraday Trade Plans - Newser
Mural Oncology to be Acquired by XOMA Royalty for $36.2 Million - AInvest
Mural Oncology to be Acquired by XOMA Royalty for $2.035-$2.24 per Share in Cash Deal - AInvest
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech - BioPharma Dive
MURA’s Unexpected Surge: Analyzing Stock Movement - StocksToTrade
Mural Oncology to be Acquired by XRA 5 - citybiz
XOMA Royalty Corporation entered into a definitive agreement to acquire Mural Oncology plc for $35.3 million. - MarketScreener
Mural Oncology plc enters acquisition agreement with XRA 5 Corp (XOMA Royalty Corporation) - Arthur Cox LLP
After culling 90% of staff, Waltham biotech finds buyer - NBC Boston
Mural Oncology’s Surprising Market Response After European Expansion - timothysykes.com
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):